Register for webinar 3 & 4

Webinar details

April 16, 2026 | 10:00am EST

Webinar overview

As conventional small molecules struggle to modulate so-called “undruggable” targets lacking accessible binding pockets, innovators are increasingly turning to targeted protein degradation (TPD), a modality that harnesses the cell’s intrinsic protein disposal machinery to selectively dismantle pathogenic proteins at their source. The surge of innovation in this space has given rise to a growing number of promising compounds that are positioned to reshape the therapeutic landscape.

This webinar explores how TPDs are transforming the industry’s approach to difficult-to-treat diseases, using our Drugs to Watch as examples:

• BGB-16673, PROTAC targeting BTK for the treatment of CLL and SLL
• Mezigdomide, a CELMoD under development for relapsed or refractory multiple myeloma

Speakers

Michael Ward (Host)

Head of Global Thought Leadership, Clarivate

As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends.

Catherine E. Willoughby, Ph.D.

Healthcare Research & Data Analyst, Oncology

Dr. Willoughby is a pharmaceutical industry analyst with over 10 years of experience in oncology research and drug discovery. She leads market forecasting and competitive intelligence projects for various hematological malignancy and solid tumor indications. Previously, she completed postdoctoral fellowships in Barcelona and earned her Ph.D. from Newcastle University, exploring novel therapeutic strategies for liver cancer.

Julia Morris

Healthcare Research & Data Analyst, Oncology

Julia Morris is a pharmaceutical industry analyst with over 10 years of experience in oncology research and drug discovery. Before joining Clarivate, Julia was a senior bioscientist in the Drug Discovery Unit at Cancer Research UK Manchester Institute, assessing the effects of preclinical small-molecule inhibitors. She earned her Ph.D. in molecular biology from the University of Sheffield.

Webinar details

May 12, 2026 | 10:00am EST

Webinar overview

Historical research paradigms often excluded women, did not prioritize female-specific diseases or failed to account for sex-based differences contributing to inequitable health outcomes. As a result, individuals with ovarian cancer still experience late diagnosis and poor survival rates, a consequence of chronic underfunding. For breast cancer, which has benefitted from awareness and funding campaigns, the unmet need has shifted to precision therapeutics for the subtypes long considered untreatable. Meanwhile, women with bladder cancer have higher risks of recurrence, progression and cancer-specific mortality than men.

This webinar explores how innovation for these cancers is transforming health outcomes, using our Drugs to Watch as examples:

• Gedatolisib, a PI3K/mTOR inhibitor for breast cancer
• INLEXZO (TAR-200), intravesical administration of gemcitabine for bladder cancer
• Relacorilant, a selective glucocorticoid receptor antagonist (SGRA) for ovarian cancer

Join us to hear what it will take for these innovations to achieve durable clinical and commercial success. We will discuss pivotal clinical data, differentiation versus standard of care, the gaps these treatments address and the long-term implications for women’s health.

Speakers

Michael Ward (Host)

Head of Global Thought Leadership, Clarivate

As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. His actionable insights and analysis support pharma, biotech, healthcare and medtech stakeholders gain a deeper understanding of market news and trends.

Arshiya Bhatt

M.Pharm- Associate Healthcare Research & Data Analyst (Immune & Inflammation)

Before joining Clarivate, Ms. Bhatt was a senior business analyst in competitive intelligence at AdametNext. She has contributed to multiple secondary and strategic projects that track competitors' regulatory, clinical, and commercial activities in immunology and oncology. She holds a master's degree with a specialization in pharmacoinformatics from the NIPER.

Glenda Walker, Ph.D.

Senior Healthcare Research & Data Analyst – Oncology

Dr. Walker is a pharmaceutical industry analyst with more than 12 years' experience, preceded by 3.5 years as a journals editor. She has authored thought leadership articles covering a broad range of pharmaceutical industry-relevant topics and therapeutic areas, including the flagship Drugs to Watch article. She holds a Ph.D. in cell biology and genetics from the University of Manchester; and was a Wellcome postdoctoral fellow at the University College London Institute of Healthy Ageing, where she used microarray approaches to investigate key proteins involved in development and aging.